Home

Recent advances in immunotherapy for cancer have led to the licensing of new biotherapeutics for prostate cancer and melanoma. However, there is a general recognition that immunotherapy alone will not be sufficient to deliver benefit to all patients.

New combinations of immunotherapy and drug treatments have led slowly to the concept that some commonly used drugs may synergize with immunotherapy. There is increasing in vitro and in vivo evidence to support the emerging concept of chemotherapy/immunotherapy combinations for cancer.

The Cancer Vaccine Institute’s 1st International Symposium on Immunotherapy will be held at The Royal Society in London on Friday 11 – Saturday 12 October 2013, with an ice-breaker drinks reception on the evening of Thursday 10th October 2013.

This important two day symposium will unite 300 clinicians and researchers to explore key areas of research into synergism between immunotherapy and standard treatments in oncology and will offer an unparalleled opportunity for the international research and clinical community to come together and explore the opportunities and challenges that exist today in immunotherapy.

Key themes of the symposium:

Key speakers

Dr James Gulley
Dr James Gulley

Senior Investigator, National Cancer Institute (NCI)

Dr Norbert Hilf
Dr Norbert Hilf

Director Translational Development, Immatics Biotechnologies GmbH, Tuebingen, Germany

Dr Wai Liu
Dr Wai Liu

Senior Research Fellow, St George's University of London

Prof Brendon Coventry
Prof Brendon Coventry

University of Adelaide

Prof Federico Garrido
Prof Federico Garrido

Professor of Immunology, Chairman Dept. Clinical Laboratory, University Hospital Virgen de las Nieves, Granada

Dr James W. Hodge PhD., MBA
Dr James W. Hodge PhD., MBA

Investigator, Head, Recombinant Vaccine Group, Laboratory of Tumor Immunology and Biology, NCI

Dr Pierpaolo Correale
Dr Pierpaolo Correale

Sienna University School of Medicine

Dr Richard Koya
Dr Richard Koya

Assistant Professor, Division of Surgery Oncology, University of California, LA

Prof. Dr. med. Dirk Jager
Prof. Dr. med. Dirk Jager

Director Medical Oncology, University Medical Center Heidelberg

Andrew Godkin
Andrew Godkin

Cardiff University

Dr Tanja de Gruijl
Dr Tanja de Gruijl

Associate Professor, VU University Medical Center

Prof I. Jolanda M. de Vries
Prof I. Jolanda M. de Vries

Professor, Dept of Tumor Immunology, Radboud University Nijmegen

Dr Androulla Elia
Dr Androulla Elia

Senior Research Fellow, St George's University of London

Mr Andrew Gravett
Mr Andrew Gravett

Research Assistant, St George's University of London

Prof. Dr. med Eckhart Kaempgen
Prof. Dr. med Eckhart Kaempgen

Partner, Dermatologikum Berlin

Prof Zvi Fridlender
Prof Zvi Fridlender

Hadassah-Hebrew University Medical Center

Prof Patrick Hwu
Prof Patrick Hwu

Anderson Cancer Centre

Prof Elizabeth Jaffee
Prof Elizabeth Jaffee

Professor of Oncology, John Hopkins University, Baltimore, Maryland

Prof Dmitry Gabrilovich
Prof Dmitry Gabrilovich

Program Leader, Translational Tumor Immunology, Wistar Institute, Philadelphia

Dr Daniel William Fowler
Dr Daniel William Fowler

Post Doctoral Research Assistant, St. George's University of London

Next Page »

Register now to take advantage of the early bird discount.

Register before 9th August 2013 to take advantage of the early bird discount and save over £40.

Symposium Fees:

Conference Websites by Miramedia